hypertension News

Merck's pipeline review this week has focused attention on its plans to develop a CETP inhibitor cholesterol drug in the same category as torcetrapib, a potential blockbuster which was recently shelved by Pfizer after researchers assessed its link to cardiovascular problems. Drug researchers have been hoping that CETP inhibitors in combination with statins will demonstrate an ability to reduce arterial plaque. Merck says that a mid-stage trial of MK-0859 reflected no change in blood …